Skip to content

The effect of Golnar Capsule (Punica Grantum) in treatment of Abnormal Uterine Bleeding

Evaluation of a Capsule of Golnar in Dysfunctional Uterine Bleeding and Comparison with Tranexamic acid

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180622040186N1
Enrollment
80
Registered
2018-06-26
Start date
2018-07-06
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DUB. Excessive and frequent menstruation with irregular cycle

Interventions

Intervention 1: Intervention group: Persian medicine capsule based on Persian Golnar 500 mg every 8 hours, from the beginning of the menstrual period to the end of the cycle. Intervention 2: Control g

Sponsors

Tehran University of Medical Sciences
Lead Sponsor
Tehran University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Women from 18 years old to 50 years old Normal Pap smear Regular Menstruation Bleeding Endometrial thickness is less than 10 mm Severe Menstruation (According to PBAC: Score>100, 80 cc) or Prolonged Menstruation (More than 7 Days ) Normal Gynecological Examination

Exclusion criteria

Exclusion criteria: Pregnancy, Plan to become pregnant in the next three months Coagulation Disorders, Systemic Diseases such as Hepatic, Renal, Thyroid, Diabetes and Chronic Inflamatory diseases FSH And LH Disorders Hemoglobin less than 10 Endometrial Disorder, Hyperplasy, Cervical, Uterine and Ovary Cancers Leiomyom and subcutaneous or internal fibroids greater than 4 cm Endometriosis Known Hemoglobinopathy Treatment with Hormonal drugs, Anti-Fibrinolytics and IUD Patients with Hypertension Patients with severe menstrual bleeding without diseases disorders

Design outcomes

Primary

MeasureTime frame
Menstrual bleeding score. Timepoint: One month before and one, two and three months after the intervention. Method of measurement: Pictorial Blood Loss Assessment Chart.;Quality of Life. Timepoint: One month before the intervention and 3 months after the intervention. Method of measurement: Aberdeen Menorrhagia Questionnaire.

Secondary

MeasureTime frame
Age. Timepoint: The beginning of the entry. Method of measurement: Question from sample.;The numbers of menstruation days. Timepoint: The number of bleeding days in 3 cycles of menstruation. Method of measurement: Day.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Es.haghee Ashtiany

Tehran University of Medical Sciences

s-eshaghee@razi.tums.ac.ir+98 21 7719 1254

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026